US medtech services firm RQM+ has acquired German contractor, clinical research organization (CRO) Kottmann.
The deal – financial terms of which were not provided – is designed to build US-based RQM+’s presence in the European Union (EU) according to COO, David Novotny.
“We are tremendously excited about this pivotal acquisition. The synergy between RQM+ and CRO Kottmann will propel us to greater heights in the industry. The German market, well known for its emphasis on science, innovation, and market intelligence, is a vital geography for RQM+."
“With the combined expertise of both organizations, we will achieve quicker, more efficient operational deliveries that will facilitate a faster market entry for our clients” Novotny said.
According to law firm DLA Piper, which worked on the deal, the acquisition “will expand RQM+’s presence in Europe and ensure comprehensive end-to-end support for clients, from pre-clinical phases to product commercialization.
“The addition of CRO Kottmann further expands RQM+'s rapidly growing business as a leading MedTech company, driving both existing and new clients’ innovations into pivotal markets.”
Pittsburgh, US-based RQM+ entered the clinical trials sector last year when it launched its specialized study services division.
At the time it said the aim is to become the partner of choice for clients that want to reduce their commercialization risk by providing all the services needed to launch their products.
Since then RQM+ has further expanded its trial services offering through acquisitions. Earlier this summer for example it bought Libra Medical, a full-service CRO that specializes in early-stage clinical trials in the US, Europe, Australia and Latin America.
The Kottmann deal also comes hot on the heels of RQM+’s purchase of Giotto Compliance from Giotto.ai.
According to a statement released at the time, Giotto aims to increase the efficiency of regulatory reports and filings across the product development lifecycle for medical device and in vitro diagnostics manufacturers.